Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies

Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure

BACKGROUND Nucleos(t)ide analogues (NUCs) treatment can reduce the risk of hepatocellular carcinoma (HCC) development and recurrence in chronic hepatitis B (CHB) patients. However, the risk of recurrence in CHB patients who develop HCC despite NUC treatment remains unclear. METHODS 167 consecutive CHB patients receiving curative resection for HCC with NUC therapy after surgery were retrospect...

Hepatitis B and hepatocellular carcinoma.

Chronic infection with the hepatitis B virus has been linked epidemiologically to the development of hepatocellular carcinoma for more than 30 years. Although the mechanisms by which chronic hepatitis B viral infection results in hepatocellular carcinoma are unclear, there is good evidence that the virus itself exerts a direct hepatocarcinogenic effect, and this has implications for prevention....

Hepatitis B-related hepatocellular carcinoma

Abstract Introduction Hepatocellular carcinoma is one of the most deadly cancers in the world and has been found to be prevalent in hepatitis B virus endemic regions. The association of hepatitis B virus as a major factor in the development of hepatocellular carcinoma has been observed in the past. However, the mechanisms of hepatocarcinogenesis are not fully understood. Multiple studies have s...

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy

Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact of interferon-alfa on the incidence of HCC is clearer in Asian patients and those with compensat...

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B